8-K: Hologic Exceeds Q3 Revenue and EPS Guidance, Refinances Debt

Hologic, Inc. reported third-quarter fiscal 2025 revenue of $1,023.8 million and non-GAAP diluted EPS of $1.08, both surpassing guidance, while also refinancing its term loan and revolving credit facility.

Summary

• Revenue for the third quarter of fiscal 2025 was $1,023.8 million, an increase of 1.2% (0.4% in constant currency), exceeding the guidance range of $1,000 million to $1,010 million.
• GAAP diluted EPS was $0.86, an increase of 4.9%, and Non-GAAP diluted EPS was $1.08, an increase of 1.9%, exceeding the high-end of the guidance range of $1.04 to $1.07.
• Diagnostics revenue was $448.9 million, up 1.8% (0.9% in constant currency), primarily driven by higher molecular diagnostics sales, partially offset by lower COVID-19 assay sales.
• Excluding COVID-19 revenue, organic diagnostics sales grew 3.9% (2.9% in constant currency).
• Molecular diagnostics revenue increased 3.2% (2.4% in constant currency), with a 6.0% (5.2% in constant currency) growth excluding COVID-19 revenue, including 7.3% growth in the United States.
• Breast Health revenue decreased (5.1%) or (5.8%) in constant currency to $365.2 million, primarily due to lower sales of mammography capital equipment, partially offset by Endomagnetics revenue and increased service contract revenue.
• Surgical revenue grew 7.1% (6.3% in constant currency) to $178.4 million, driven by the acquired Gynesonics business and strong international sales.
• Skeletal health revenue increased significantly by 64.7% (62.1% in constant currency) to $31.3 million.
• Cash flow from operations was a strong $343.2 million in the third quarter.
• The company refinanced its term loan and revolving credit facility in July 2025, establishing a $1.17 billion term loan and a $1.25 billion revolver maturing in July 2030.
• Repurchased 0.7 million shares for $36 million during the third quarter of fiscal 2025.
• Ended the quarter with cash and cash equivalents of $1.74 billion and an adjusted net leverage ratio of 0.6 times.
• Adjusted Return on Invested Capital (ROIC) was 13.9%, a decrease of (20) basis points compared to the prior year period.
• COVID-19 revenue, including assays and other related sales, decreased (17.1%) or (17.8%) in constant currency to $31.5 million.

Sentiment

Score: 7

Explanation: The company exceeded its own revenue and non-GAAP EPS guidance for the quarter, demonstrating strong operational execution. Key financial metrics like cash flow from operations and net leverage ratio are healthy. The successful refinancing of debt improves the company's financial flexibility. However, some core segments like Breast Health (mammography capital equipment) experienced declines, and overall organic revenue growth (excluding COVID-19) was modest. The positive outlook for Q4 and full year 2025, with expected faster non-GAAP EPS growth, contributes to a generally positive sentiment.

Positives

• Revenue of $1,023.8 million exceeded the company's guidance range of $1,000 million to $1,010 million.
• Non-GAAP Diluted EPS of $1.08 exceeded the high-end of the company's guidance range of $1.04 to $1.07.
• Strong cash flow from operations of $343.2 million in the third quarter.
• Successful refinancing of term loan and revolving credit facility, extending maturity to July 2030, enhancing financial flexibility.
• Low adjusted net leverage ratio of 0.6 times indicates strong financial health and capacity.
• International revenue increased by 6.9% (3.5% in constant currency), demonstrating strong performance outside the U.S.
• Molecular diagnostics revenue (excluding COVID-19) grew 6.0% (5.2% in constant currency), with robust 7.3% growth in the United States.
• Surgical revenue grew 7.1% (6.3% in constant currency), driven by strategic acquisitions and strong international sales.
• Skeletal health revenue showed exceptional growth of 64.7% (62.1% in constant currency).
• The company remains on track for solid revenue growth and faster non-GAAP EPS growth in the fourth quarter.

Negatives

• Breast Health revenue decreased (5.1%) or (5.8%) in constant currency, primarily due to lower sales of mammography capital equipment.
• Organic breast health revenue, excluding recent acquisitions and divestitures, decreased (10.1%) or (10.8%) in constant currency.
• COVID-19 related revenue continued to decline, decreasing (17.1%) or (17.8%) in constant currency.
• Non-GAAP gross margin decreased (80) basis points to 60.3%, attributed to product mix and increased reserves.
• Non-GAAP operating margin decreased (110) basis points to 30.1%, primarily due to expected margin dilution from the inclusion of Endomagnetics and Gynesonics results.
• Non-GAAP net income decreased (2.6%) to $244.1 million.
• Adjusted Return on Invested Capital (ROIC) decreased (20) basis points to 13.9%.
• U.S. revenue decreased (0.6%).
• GAAP EPS guidance for the full fiscal year 2025 projects a significant decrease of (22.9%) to (22.0%).

Risks

• The development of new or improved competitive technologies and products and general competition in the market.
• The company's ability to accurately predict demand for its products and products under development, and to successfully address markets.
• The effect of consolidation within the healthcare industry.
• The ability to execute acquisitions and the impact and anticipated benefits of completed and future acquisitions.
• Coverage and reimbursement decisions made by third-party payors.
• The uncertainty of the impact of cost containment efforts and federal healthcare reform legislation on business and results of operations.
• Guidelines, recommendations, and studies published by various organizations relating to the use of the company's products.
• The company's ability to obtain and maintain regulatory approvals and clearances for its products, including compliance with EU Medical Device and In Vitro Diagnostic Regulation requirements, and evolving regulations and quality standards.
• The possibility that products may contain undetected errors or defects or otherwise not perform as anticipated.
• The impact, costs, and expenses of investigative and legal proceedings and compliance risks.
• Potential negative impacts resulting from climate change or other environmental, social, and governance (ESG) related matters.
• The impact of future tax legislation.
• Ongoing and possible future effects of global challenges, including macroeconomic uncertainties such as inflation, bank failures, rising interest rates, and availability of capital markets, wars, conflicts, other economic disruptions, and U.S. and global recession concerns, on customers, suppliers, business, financial condition, results of operations, and cash flows.
• The effect of worldwide political and social uncertainty and divisions, including the impact on trade regulations and tariffs, which may adversely impact the cost and sale of products or increase material purchase costs.
• Risks associated with conducting business internationally.
• Potential cybersecurity threats and targeted computer crime.
• Ongoing and possible future effects of supply chain constraints, including the availability of critical raw materials and components, as well as cost inflation in materials, packaging, and transportation.
• The possibility of interruptions or delays at manufacturing facilities, or the failure to secure alternative suppliers if sole source third-party manufacturers fail to supply.
• The ability to consolidate certain manufacturing and other operations on a timely basis and within budget, without disrupting business and achieving anticipated cost synergies.
• The company's ability to meet production and delivery schedules for its products.
• The effect of any future public health pandemic or other crises, including governmental, regulatory, fiscal, monetary, and public health responses.
• The ability to successfully manage ongoing organizational and strategic changes, including attracting, motivating, and retaining key employees and maintaining engagement and efficiency in remote work environments.
• The company's ability to protect its intellectual property rights.
• Anticipated trends relating to the company's financial condition or results of operations, including the impact of interest rate and foreign currency exchange fluctuations.
• Estimated asset and liability values.
• Compliance with covenants contained in the company's debt agreements.
• The company's liquidity, capital resources, and the adequacy thereof.

Future Outlook

For the fourth quarter of fiscal 2025, Hologic expects revenue between $1,030 million and $1,040 million, representing 4.3% to 5.3% reported growth and 3.9% to 5.0% organic growth excluding COVID-19. Non-GAAP EPS is projected to be between $1.09 and $1.12, indicating 7.9% to 10.9% growth. For the full fiscal year 2025, the company forecasts revenue of $4,081 million to $4,091 million (1.3% to 1.5% reported growth, 0.6% to 0.8% organic excluding COVID-19) and Non-GAAP EPS of $4.23 to $4.26 (3.7% to 4.4% growth). The company anticipates mid-single-digit growth in organic, constant currency revenue excluding COVID-19 in Q4, with non-GAAP earnings per share growing faster than revenue, partly due to tariff mitigation efforts.

Management Comments

• "We are pleased to have delivered revenue and non-GAAP earnings growth in the third quarter that exceeded our guidance ranges." Stephen P. MacMillan, Chairman, President and Chief Executive Officer.
• "And we made great progress toward returning to better topand bottom-line growth in the fourth quarter, driven by the continued rebound of our Breast Health business and solid performances by our other divisions." Stephen P. MacMillan, Chairman, President and Chief Executive Officer.
• "Building on our solid third-quarter performance, in the fourth quarter we continue to expect mid-single-digit growth in organic, constant currency revenue excluding COVID." Karleen Oberton, Chief Financial Officer.
• "We also forecast non-GAAP earnings per share will grow faster than revenue, helped in part by our tariff mitigation efforts." Karleen Oberton, Chief Financial Officer.

Industry Context

Hologic operates in the medical technology sector, with a primary focus on women's health, diagnostics, and surgical solutions. The reported decline in COVID-19 related revenue aligns with broader industry trends as the pandemic's impact diminishes. The growth in molecular diagnostics (excluding COVID-19) and surgical segments reflects strength in core, non-pandemic-related areas, indicating a successful pivot back to foundational business lines. The decrease in mammography capital equipment sales within Breast Health suggests potential cyclical demand or market saturation in that specific sub-segment. The company's strategic acquisitions, such as Endomagnetics and Gynesonics, demonstrate a continued industry trend of expanding product portfolios and market reach through M&A to drive growth in specialized medical fields.

Legal Proceedings

• The company acknowledges the risk of impact and costs from investigative and legal proceedings and compliance risks it may be subject to now or in the future.

Stakeholder Impact

• Shareholders: Positive impact due to exceeding guidance, strong cash flow, debt refinancing, and share repurchases, indicating financial stability and potential for continued non-GAAP EPS growth.
• Employees: No direct impact mentioned, but strong financial performance and strategic growth initiatives could imply job stability and potential opportunities.
• Customers: Continued product development and strategic acquisitions aim to enhance product offerings and improve patient outcomes.
• Suppliers: Mention of supply chain constraints and cost inflation as risks could potentially impact supplier relationships and procurement strategies.
• Creditors: Positive impact from successful debt refinancing and a strong net leverage ratio, indicating a healthy ability to manage debt obligations.

Next Steps

• Continue efforts to return to better topand bottom-line growth in the fourth quarter.
• Leverage tariff mitigation efforts to support non-GAAP EPS growth.
• Revenue from the acquired Endomagnetics business will become organic in August of fiscal 2025.
• Host a conference call on July 30, 2025, to discuss financial results with investors.

Key Dates

Recommendation

While Hologic exceeded its Q3 guidance for revenue and non-GAAP EPS, demonstrating operational strength and effective debt management, the underlying organic revenue growth (excluding COVID-19) remains modest at (0.8%) reported or (1.7%) constant currency. The Breast Health segment, a significant part of the business, experienced a notable decline in revenue, particularly in mammography capital equipment. Although the company projects mid-single-digit organic growth for Q4, the overall picture presents a mix of strengths and challenges. The stock may be fairly valued given the current growth trajectory and market conditions. A "hold" recommendation reflects the balance between positive financial execution and ongoing segment-specific headwinds, suggesting investors monitor future organic growth trends and the rebound of the Breast Health business before making significant new positions.

Keywords

Medical Technology, Women's Health, Diagnostics, Breast Health, Molecular Diagnostics, Surgical, Skeletal Health, Financial Results, Earnings, Revenue, EPS, SEC Filing, Hologic, HOLX, Q3 2025, Corporate Finance, Debt Refinancing, Investor Relations